Berkshire Hathaway Reduces Stake in DaVita: What Happened and Key Takeaways

This week, it was revealed that Berkshire Hathaway (BRKa.N), led by the legendary Warren Buffett, has reduced its holdings in DaVita Inc. (DVA.N), one of the largest providers of kidney dialysis services. This decision, disclosed in a regulatory filing, has garnered significant attention from market participants. Let’s delve into the reasons behind this move and the current state of this investment.

The History of Berkshire Hathaway’s Investment in DaVita

Berkshire Hathaway first acquired shares in DaVita at the end of 2011. This initiative was linked to Ted Weschler, who joined Buffett’s team in 2012. Weschler had previously shown interest in the company, investing in it through his hedge fund, Peninsula Capital Advisors.  

At the time of purchase, DaVita was an attractive company with a stable business in the medical services sector, providing essential treatment to patients with chronic kidney conditions.

Why Berkshire Hathaway is Reducing Its Stake in DaVita

In February 2024, Berkshire Hathaway announced it had sold 203,091 shares of DaVita, bringing its stake in the company down to 35.89 million shares or 45%. The total value of its remaining holdings in DaVita is estimated to be around $6.4 billion. The reasons for the sale are rooted not in a desire to exit the investment but in contractual obligations.

Key Factors Influencing the Decision:

• Share Repurchase Agreement. In April 2024, an agreement was made between Berkshire Hathaway and DaVita, obligating the latter to repurchase enough of its own shares each quarter to reduce Berkshire’s stake to 45%.
• Voting Rights Limitation. According to the agreement, all shares owned by Berkshire exceeding 40% must vote in line with the recommendations of DaVita’s Board of Directors. This approach is likely aimed at minimizing the influence of a major shareholder on the company’s internal policies.
• Long-Term Asset Management Strategy. Despite reducing its stake, Berkshire remains DaVita’s largest shareholder, which underscores its long-term interest and support for the business in this sector.

The Significance for DaVita and Berkshire Hathaway

The sale of part of its holdings does not signify an end to the partnership. On the contrary, this move appears to be a continuation of a strategic dialogue between the two companies. However, this event does carry certain implications for both parties.

For DaVita:

1. A more balanced distribution of shares among shareholders.  
2. Increased investor attention due to Berkshire’s actions.

For Berkshire Hathaway:

1. Maintained significant influence on DaVita’s business.  
2. The sale of part of its assets can signal adherence to new regulatory norms, reaffirming the company’s reputation.

Insight into Berkshire Hathaway’s Investment Strategy

The decision to partially sell its DaVita shares illustrates one of Berkshire Hathaway’s key asset management principles – respect for regulations and a long-term growth strategy. The DaVita case serves as a reminder that even the largest market players do not make decisions solely based on short-term market fluctuations.

Conclusion

The sale of part of its DaVita assets is a step aligned with agreements and internal strategies at Berkshire Hathaway. Despite this, DaVita shares continue to hold a significant position in Buffett’s portfolio, reflecting his commitment to the healthcare sector. This case highlights Berkshire’s careful and measured approach to investments and its willingness to adapt in response to evolving market requirements.